

Subject index

Volume 52 (2001)

Acyclovir; Herpes simplex virus; Latent infection; Reactivation; Neuron; Penciclovir **52**, 19

Adenovirus; Anti-adenovirus; NMSO3; Adsorption inhibitor; MTT method **52**, 281

Adenovirus; Antiviral drugs; Cidofovir; Epidemic keratoconjunctivitis **52**, 275

Adsorption inhibitor; Adenovirus; Anti-adenovirus; NMSO3; MTT method **52**, 281

Adult-to-adult; Liver transplantation; Donor shortage **52**, 217

Anti-adenovirus; Adenovirus; NMSO3; Adsorption inhibitor; MTT method **52**, 281

Anti-E2 antibody; GB virus C/hepatitis G virus RNA; Hepatitis C virus; Interferon **52**, 241

Antimicrobial properties; Lactoferrin; Glycoprotein; Antiviral **52**, 225

Antiviral; Cytomegalovirus; β -galactosidase; Ganciclovir **52**, 289

Antiviral drugs; Adenovirus; Cidofovir; Epidemic keratoconjunctivitis **52**, 275

Antiviral effect; Serum amyloid P component; Influenza A virus **52**, 43

Antiviral; Lactoferrin; Glycoprotein; Antimicrobial properties **52**, 225

Antiviral; Neuraminidase inhibitor; Influenza virus; Drug resistance **52**, 251

Antiviral therapy; Hepatitis C Virus; HCV cell cultures; Flaviviridae; HCV replication systems; HCV replicons **52**, 1

Antiviral; Vaccinia virus; Pathogenesis; Cidofovir **52**, 55

Aziridine; Virus inactivation; Ethyleneimine; Protein modification; Semliki forest virus; Minute virus of mice **52**, 33

Chronic hepatitis B; Interferon-alpha; Lamivudine; Combination therapy; Hepatitis B e-antigen seroconversion **52**, 139

Chronic hepatitis B virus infection; Ribavirin therapeutic use; Interferon- α therapeutic use **52**, 147

Cidofovir; Antiviral drugs; Adenovirus; Epidemic keratoconjunctivitis **52**, 275

Cidofovir; Vaccinia virus; Pathogenesis; Antiviral **52**, 55

Cirrhosis; Hepatocellular carcinoma (HCC); Hepatitis B virus (HBV); Hepatitis C virus (HCV) **52**, 199

Coinfection; GBV-C; HGV; HIV; Hepatitis; Survival **52**, 83

Combination therapy; Chronic hepatitis B; Interferon-alpha; Lamivudine; Hepatitis B e-antigen seroconversion **52**, 139

Cytomegalovirus; β -galactosidase; Ganciclovir; Antiviral **52**, 289

Docusate; Herpes simplex virus; Preclinical evaluation **52**, 25

Donor shortage; Adult-to-adult; Liver transplantation **52**, 217

Drug resistance; Antiviral; Neuraminidase inhibitor; Influenza virus **52**, 251

Entry inhibitor; Peptide T; Macrophage; HIV-1; Therapeutic **52**, 63

Epidemic keratoconjunctivitis; Antiviral drugs; Adenovirus; Cidofovir **52**, 275

Ethyleneimine; Virus inactivation; Aziridine; Protein modification; Semliki forest virus; Minute virus of mice **52, 33**

Flaviviridae family; Hepatitis C virus; Necroinflammation; Steatosis **52, 161**

Flaviviridae; Hepatitis C Virus; HCV cell cultures; Antiviral therapy; HCV replication systems; HCV replicons **52, 1**

β -galactosidase; Cytomegalovirus; Ganciclovir; Antiviral **52, 289**

Gamma photons; Ionizing radiation; Neutrons; Influenza A virus **52, 261**

Ganciclovir; Cytomegalovirus; β -galactosidase; Antiviral **52, 289**

GBV-C; HGV; HIV; Coinfection; Hepatitis; Survival **52, 83**

GB virus C/hepatitis G virus RNA; Anti-E2 antibody; Hepatitis C virus; Interferon **52, 241**

Gene expression profiling; Hepatitis C virus; Messenger RNAs **52, 173**

Genetic variants; Hepatitis B virus; Pathogenesis **52, 125**

Glycoprotein; Lactoferrin; Antimicrobial properties; Antiviral **52, 225**

HAART; Hepatitis C virus; HIV; Interferon; Ribavirin; Liver disease **52, 189**

HBV DNA levels; HCV RNA levels; Interleukin-12; Interferon- γ ; Interleukin-10 **52, 181**

HBV infection; Lack of HBsAg detection **52, 117**

HCV cell cultures; Hepatitis C Virus; Antiviral therapy; Flaviviridae; HCV replication systems; HCV replicons **52, 1**

HCV replication systems; Hepatitis C Virus; HCV cell cultures; Antiviral therapy; Flaviviridae; HCV replicons **52, 1**

HCV replicons; Hepatitis C Virus; HCV cell cultures; Antiviral therapy; Flaviviridae; HCV replication systems **52, 1**

HCV RNA levels; HBV DNA levels; Interleukin-12; Interferon- γ ; Interleukin-10 **52, 181**

Hepatic resection; Hepatocellular carcinoma; Liver transplantation; Percutaneous ablation **52, 209**

Hepatitis B e-antigen; Hepatitis B virus; T-cell receptor; Transgenic mice **52, 99**

Hepatitis B e-antigen seroconversion; Chronic hepatitis B; Interferon-alpha; Lamivudine; Combination therapy **52, 139**

Hepatitis B surface antigen; Hepatitis B virus; Hepatitis C virus **52, 113**

Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Cirrhosis; Hepatitis C virus (HCV) **52, 199**

Hepatitis B virus; Hepatitis C virus; Hepatitis B surface antigen **52, 113**

Hepatitis B virus; Pathogenesis; Genetic variants **52, 125**

Hepatitis B virus; T-cell receptor; Transgenic mice; Hepatitis B e-antigen **52, 99**

Hepatitis C virus; GB virus C/hepatitis G virus RNA; Anti-E2 antibody; Interferon **52, 241**

Hepatitis C virus; Gene expression profiling; Messenger RNAs **52, 173**

Hepatitis C Virus; HCV cell cultures; Antiviral therapy; Flaviviridae; HCV replication systems; HCV replicons **52, 1**

Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Cirrhosis; Hepatitis B virus (HBV) **52, 199**

Hepatitis C virus; Hepatitis B virus; Hepatitis B surface antigen **52, 113**

Hepatitis C virus; HIV; HAART; Interferon; Ribavirin; Liver disease **52, 189**

Hepatitis C virus; Hypervariable region 1; Immune response; Monoclonal antibodies **52, 153**

Hepatitis C virus; Necroinflammation; Flaviviridae family; Steatosis **52, 161**

Hepatitis; GBV-C; HGV; HIV; Coinfection; Survival **52, 83**

Hepatocellular carcinoma (HCC); Cirrhosis; Hepatitis B virus (HBV); Hepatitis C virus (HCV) **52, 199**

Hepatocellular carcinoma; Hepatic resection; Liver transplantation; Percutaneous ablation **52, 209**

Herpes simplex virus; Docusate; Preclinical evaluation **52, 25**

Herpes simplex virus; Latent infection; Reactivation; Neuron; Acyclovir; Penciclovir **52**, 19

HGV; GBV-C; HIV; Coinfection; Hepatitis; Survival **52**, 83

HIV; GBV-C; HGV; Coinfection; Hepatitis; Survival **52**, 83

HIV; Hepatitis C virus; HAART; Interferon; Ribavirin; Liver disease **52**, 189

HIV-1; Peptide T; Macrophage; Entry inhibitor; Therapeutic **52**, 63

Hypervariable region 1; Hepatitis C virus; Immune response; Monoclonal antibodies **52**, 153

Immune response; Hepatitis C virus; Hypervariable region 1; Monoclonal antibodies **52**, 153

Influenza A virus; Antiviral effect; Serum amyloid P component **52**, 43

Influenza A virus; Ionizing radiation; Gamma photons; Neutrons **52**, 261

Influenza virus; Antiviral; Neuraminidase inhibitor; Drug resistance **52**, 251

Interferon-alpha; Chronic hepatitis B; Lamivudine; Combination therapy; Hepatitis B e-antigen seroconversion **52**, 139

Interferon; GB virus C/hepatitis G virus RNA; Anti-E2 antibody; Hepatitis C virus **52**, 241

Interferon-γ; HBV DNA levels; HCV RNA levels; Interleukin-12; Interleukin-10 **52**, 181

Interferon; Hepatitis C virus; HIV; HAART; Ribavirin; Liver disease **52**, 189

Interferon-α therapeutic use; Chronic hepatitis B virus infection; Ribavirin therapeutic use **52**, 147

Interleukin-12; HBV DNA levels; HCV RNA levels; Interferon-γ; Interleukin-10 **52**, 181

Interleukin-10; HBV DNA levels; HCV RNA levels; Interleukin-12; Interferon-γ **52**, 181

Ionizing radiation; Gamma photons; Neutrons; Influenza A virus **52**, 261

Lack of HBsAg detection; HBV infection **52**, 117

Lactoferrin; Glycoprotein; Antimicrobial properties; Antiviral **52**, 225

Lamivudine; Chronic hepatitis B; Interferon-alpha; Combination therapy; Hepatitis B e-antigen seroconversion **52**, 139

Latent infection; Herpes simplex virus; Reactivation; Neuron; Acyclovir; Penciclovir **52**, 19

Liver disease; Hepatitis C virus; HIV; HAART; Interferon; Ribavirin **52**, 189

Liver transplantation; Adult-to-adult; Donor shortage **52**, 217

Liver transplantation; Hepatocellular carcinoma; Hepatic resection; Percutaneous ablation **52**, 209

Macrophage; Peptide T; HIV-1; Entry inhibitor; Therapeutic **52**, 63

Messenger RNAs; Gene expression profiling; Hepatitis C virus **52**, 173

Minute virus of mice; Virus inactivation; Ethyleneimine; Aziridine; Protein modification; Semliki forest virus **52**, 33

Monoclonal antibodies; Hepatitis C virus; Hypervariable region 1; Immune response **52**, 153

MTT method; Adenovirus; Anti-adenovirus; NMSO3; Adsorption inhibitor **52**, 281

Necroinflammation; Hepatitis C virus; Flaviviridae family; Steatosis **52**, 161

Neuraminidase inhibitor; Antiviral; Influenza virus; Drug resistance **52**, 251

Neuron; Herpes simplex virus; Latent infection; Reactivation; Acyclovir; Penciclovir **52**, 19

Neutrons; Ionizing radiation; Gamma photons; Influenza A virus **52**, 261

NMSO3; Adenovirus; Anti-adenovirus; Adsorption inhibitor; MTT method **52**, 281

Pathogenesis; Hepatitis B virus; Genetic variants **52**, 125

Pathogenesis; Vaccinia virus; Cidofovir; Antiviral **52**, 55

Penciclovir; Herpes simplex virus; Latent infection; Reactivation; Neuron; Acyclovir **52**, 19

Peptide T; Macrophage; HIV-1; Entry inhibitor; Therapeutic **52**, 63

Percutaneous ablation; Hepatocellular carcinoma; Hepatic resection; Liver transplantation **52**, 209

Preclinical evaluation; Docusate; Herpes simplex virus **52**, 25

Protein modification; Virus inactivation; Ethyleneimine; Aziridine; Semliki forest virus; Minute virus of mice **52**, 33

Reactivation; Herpes simplex virus; Latent infection; Neuron; Acyclovir; Penciclovir **52**, 19

Ribavirin; Hepatitis C virus; HIV; HAART; Interferon; Liver disease **52**, 189

Ribavirin therapeutic use; Chronic hepatitis B virus infection; Interferon- α therapeutic use **52**, 147

Semliki forest virus; Virus inactivation; Ethyleneimine; Aziridine; Protein modification; Minute virus of mice **52**, 33

Serum amyloid P component; Antiviral effect; Influenza A virus **52**, 43

Steatosis; Hepatitis C virus; Necroinflammation; Flaviviridae family **52**, 161

Survival; GBV-C; HGV; HIV; Coinfection; Hepatitis **52**, 83

T-cell receptor; Hepatitis B virus; Transgenic mice; Hepatitis B e-antigen **52**, 99

Therapeutic; Peptide T; Macrophage; HIV-1; Entry inhibitor **52**, 63

Transgenic mice; Hepatitis B virus; T-cell receptor; Hepatitis B e-antigen **52**, 99

Vaccinia virus; Pathogenesis; Cidofovir; Antiviral **52**, 55

Virus inactivation; Ethyleneimine; Aziridine; Protein modification; Semliki forest virus; Minute virus of mice **52**, 33